Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome.

Next Previous
Trial Profile

CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CER 001 (Primary)
  • Indications Acute coronary syndromes; Atherosclerosis
  • Focus Therapeutic Use
  • Acronyms CHI SQUARE
  • Sponsors ABIONYX Pharma; Cerenis Therapeutics

Most Recent Events

  • 29 Apr 2014 Primary endpoint 'Plaque-volume' has not been met according to results published in European Heart Journal.
  • 29 Apr 2014 Results published in the European Heart Journal.
  • 28 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top